Cancer Clinical Trials
This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Resected Pancreatic Cancer
Trial Name: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.
Protocol ID: RTOG 0848
Enrollment: Enrollment: 950 participants
Taking part in this study may or may not make your health better. It has been proven that gemcitabine will reduce the chance that this cancer will come back and that this will increase your lifespan. It is not proven whether the addition of erlotinib to gemcitabine or the addition of radiation and fluoropyrimidine following gemcitabine will reduce the risk of pancreatic cancer recurring for patients with pancreatic cancer that has already been removed. Based on other studies there are reasons to believe that these treatments may be helpful and this trial is being done to try to find out whether they really are. We do know that the information from this study will help researchers learn more about the treatment of pancreatic cancer. This information could help future cancer patients.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.
Created: Jul 15, 2010
Updated: Jul 19, 2013